Full name

REIMAGINE - A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma

NCT Number
NCT06041386
Geography
US
Non-US
Locations

Belgium, Canada, France, Germany, Italy, Japan, Poland, Spain, United States

Primary Endpoints

Percentage (%) of Participants Achieving 4-Component Clinical Remission* at month 12

External Link
https://clinicaltrials.gov/study/NCT06041386
Order
3
Disease
Asthma
Menu title
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Version
NMA 2025
Phase
4
Status
Recruiting
Footnotes

*4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function.